Evidence map›Paper›PMID 34405894›Full record

ReviewJournal of child psychology and psychiatry, and allied disciplines2021

Ethical dimensions of translational developmental neuroscience research in autism.

Arianna Manzini, Emily J H Jones, Tony Charman, Mayada Elsabbagh, Mark H Johnson, Ilina Singh

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of child psychology and psychiatry, and allied disciplines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Complementary and Alternative Medicine for Autism - A Systematic Review.Journal of autism and developmental disorders · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Quo Vadis translational neuroscience?Translational neuroscience · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 2 countries.

Arianna ManziniCentre for Ethics in Medicine, University of Bristol, Bristol, UK.ORCID 0000-0001-7710-8974
Emily J H JonesCentre for Brain and Cognitive Development, Birkbeck, University of London, London, UK.ORCID 0000-0001-5747-9540
Tony CharmanInstitute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.ORCID 0000-0003-1993-6549
Mayada ElsabbaghAzrieli Centre for Autism Research, Montreal Neurological Institute-Hospital, McGill University, Montreal, QC, Canada.
Mark H JohnsonCentre for Brain and Cognitive Development, Birkbeck, University of London, London, UK.
Ilina SinghDepartment of Psychiatry and Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, UK.ORCID 0000-0003-4497-3587
Birkbeck, University of London · GBKing's College London · GBMontreal Neurological Institute and Hospital · CAUniversity of Bristol · GBUniversity of Cambridge · GBUniversity of Oxford · GB

Funding

CIHRDepartment of Health IS-BRC-1215-20005Medical Research Council MR/K021389/1Medical Research Council MR/T003057/1Wellcome Trust 104825Wellcome Trust 104825/Z/14/ZWellcome Trust 203132Wellcome Trust 203132/Z/16/ZWellcome Trust 203329Wellcome Trust 203329/Z/16/ZWellcome Trust 221455/Z/20/Z
6 · The paper itself

Abstract

backgroundSince the 1990s, increasing research has been devoted to the identification of biomarkers for autism to help attain more objective diagnosis; enable early prediction of prognosis; and guide individualized intervention options. Early studies focused on the identification of genetic variants associated with autism, but more recently, research has expanded to investigate neurodevelopmental markers. While ethicists have extensively discussed issues around advances in autism genomics, much less ethical scrutiny has focused on research on early neurodevelopment and on the interventions being developed as a result.

objectivesWe summarize the current state of the science on the identification of early markers for autism and its potential clinical applications, before providing an overview of the ethical issues arising from increasing understanding of children's neurodevelopment in very early life.

resultsAdvances in the understanding of brain and behavioral trajectories preceding later autism diagnosis raise ethical concerns around three themes: (a) New models for understanding autism; (b) Risks and benefits of early identification and intervention; and (c) Communication of early concerns to families. These ethical issues should be further investigated in research conducted in partnership with autistic people and their families.

conclusionsThis paper highlights the need for ethical scrutiny of early neurodevelopmental research in autism. Scrutiny requires expertise and methods from the basic sciences and bioethics, as well as constructive collaborations among autistic people, their parents, and autism researchers to anticipate early interventions that serve the community's interests and accommodate the varied experiences and preferences of people on the spectrum and their families.

Indexed as

Autism Spectrum DisorderAutistic DisorderNeurosciencesBrainChildEarly Intervention, EducationalHumansParentsAutismbiomarkersethicsgeneticsinfant siblingsneurodevelopment

Identifiers

PMID34405894
PMCPMC7611913
OpenAlexW3176566720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.